Antiviral activity of the dihydropyrone PNU-140690, a new nonpeptidic human immunodeficiency virus protease inhibitor
- 1 May 1997
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 41 (5) , 1058-1063
- https://doi.org/10.1128/aac.41.5.1058
Abstract
PNU-140690 is a member of a new class of nonpeptidic human immunodeficiency virus (HIV) protease inhibitors (sulfonamide-containing 5,6-dihydro-4-hydroxy-2-pyrones) discovered by structure-based design. PNU-140690 has excellent potency against a variety of HIV type 1 (HIV-1) laboratory strains and clinical isolates, including those resistant to the reverse transcriptase inhibitors zidovudine or delavirdine. When combined with either zidovudine or delavirdine, PNU-140690 contributes to synergistic antiviral activity. PNU-140690 is also highly active against HIV-1 variants resistant to peptidomimetic protease inhibitors, underscoring the structural distinctions between PNU-140690 and substrate analog protease inhibitors. PNU-140690 retains good antiviral activity in vitro in the presence of human plasma proteins, and preclinical pharmacokinetic studies revealed good oral bioavailability. Accordingly, PNU-140690 is a candidate for clinical evaluation.Keywords
This publication has 21 references indexed in Scilit:
- Structure-Based Design of HIV Protease Inhibitors: Sulfonamide-Containing 5,6-Dihydro-4-hydroxy-2-pyrones as Non-Peptidic InhibitorsJournal of Medicinal Chemistry, 1996
- Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitorsAntimicrobial Agents and Chemotherapy, 1995
- In vivo emergence of HIV-1 variants resistant to multiple protease inhibitorsNature, 1995
- Reduction Of The In Vitro Activity Of A77003, An Inhibitor Of Human Immunodeficiency Virus Protease, By Human Serum 1 Acid GlycoproteinThe Journal of Infectious Diseases, 1995
- Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infectionNature, 1995
- Bisheteroarylpiperazine reverse transcriptase inhibitor in combination with 3'-azido-3'-deoxythymidine or 2',3'-dideoxycytidine synergistically inhibits human immunodeficiency virus type 1 replication in vitroAntimicrobial Agents and Chemotherapy, 1994
- U-90152, a potent inhibitor of human immunodeficiency virus type 1 replicationAntimicrobial Agents and Chemotherapy, 1993
- Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. The RV-43 Study Group, the AIDS Clinical Trials Group Virology Committee Resistance Working GroupAntimicrobial Agents and Chemotherapy, 1993
- Resistance to ddI and Sensitivity to AZT Induced by a Mutation in HIV-1 Reverse TranscriptaseScience, 1991
- Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assaysJournal of Immunological Methods, 1983